@inbook{025e6dc0c54348558eed6021a56306b3,
title = "Regulation of glucose homeostasis by GLP-1",
abstract = "Glucagon-like peptide-1(7-36)amide (GLP-1) is a secreted peptide that acts as a key determinant of blood glucose homeostasis by virtue of its abilities to slow gastric emptying, to enhance pancreatic insulin secretion, and to suppress pancreatic glucagon secretion. GLP-1 is secreted from L cells of the gastrointestinal mucosa in response to a meal, and the blood glucose-lowering action of GLP-1 is terminated due to its enzymatic degradation by dipeptidyl-peptidase-IV (DPP-IV). Released GLP-1 activates enteric and autonomic reflexes while also circulating as an incretin hormone to control endocrine pancreas function. The GLP-1 receptor (GLP-1R) is a G protein-coupled receptor that is activated directly or indirectly by blood glucose-lowering agents currently in use for the treatment of type 2 diabetes mellitus (T2DM). These therapeutic agents include GLP-1R agonists (exenatide, liraglutide, lixisenatide, albiglutide, dulaglutide, and langlenatide) and DPP-IV inhibitors (sitagliptin, vildagliptin, saxagliptin, linagliptin, and alogliptin). Investigational agents for use in the treatment of T2DM include GPR119 and GPR40 receptor agonists that stimulate the release of GLP-1 from L cells. Summarized here is the role of GLP-1 to control blood glucose homeostasis, with special emphasis on the advantages and limitations of GLP-1-based therapeutics.",
keywords = "Diabetes, GLP-1, Glucagon, Glucose, Hyperglycemia, Incretin hormone, Insulin",
author = "Prashant Nadkarni and Chepurny, \{Oleg G.\} and Holz, \{George G.\}",
year = "2014",
doi = "10.1016/B978-0-12-800101-1.00002-8",
language = "English",
isbn = "9780128001011",
series = "Progress in Molecular Biology and Translational Science",
publisher = "Elsevier B.V.",
pages = "23--65",
booktitle = "Glucose Homeostatis and the Pathogenesis of Diabetes Mellitus",
}